title: Repeat cytoreductive surgery with hyperthermic intraperitoneal chemotherapy: review of indications and outcomes.
abstract: Cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC) is an established treatment option in selected patients with peritoneal dissemination from a variety of epithelial primaries. Even though a small proportion will be alive and potentially cured at 10 years, the majority will eventually develop recurrent disease. Repeat CRS/HIPEC is a valid consideration in a selected subpopulation of patients with isolated peritoneal recurrence. This review summarizes the data on patient selection, feasibility, limitations and outcomes of repeat CRS/HIPEC.
authors.affiliation: Division of Surgical Oncology, Department of General Surgery, Wake Forest University, Winston-Salem, NC, USA.
authors.forename: Harveshp
authors.initials: H
authors.lastname: Mogal
authors.affiliation: Division of Surgical Oncology, Department of General Surgery, Wake Forest University, Winston-Salem, NC, USA.
authors.forename: Konstantinos
authors.initials: K
authors.lastname: Chouliaras
authors.affiliation: Division of Surgical Oncology, Department of General Surgery, Wake Forest University, Winston-Salem, NC, USA.
authors.forename: Edward A
authors.initials: EA
authors.lastname: Levine
authors.affiliation: Division of Surgical Oncology, Department of General Surgery, Wake Forest University, Winston-Salem, NC, USA.
authors.forename: Perry
authors.initials: P
authors.lastname: Shen
authors.affiliation: Division of Surgical Oncology, Department of General Surgery, Wake Forest University, Winston-Salem, NC, USA.
authors.forename: Konstantinos I
authors.initials: KI
authors.lastname: Votanopoulos
keywords: Repeat cytoreduction; hyperthermic intraperitoneal chemotherapy (HIPEC)